Stephen M Keefe

faculty photo
Ann B. Young Assistant Professor in Cancer Research
Department: Medicine

Contact information
16 Penn Tower
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-6319
Fax: 215-662-2432
B.S.E.E. (Electrical Engineering)
University of Notre Dame, 1993.
B.A. (Philosophy)
University of Notre Dame, 1993.
Certif. (Post-Baccalaureate Program in Pre-Medical Studies)
Columbia University, 1997.
M.D. (Internal Medicine)
Pritzker School of Medicine, University of Chicago, 2003.
M.S.C.E. (Clinical Epidemiology & Biostatistics, anticipated)
Perelman School of Medicine, University of Pennsylvania, 2014.
Permanent link

Description of Itmat Expertise

Clinically-oriented translational investigator in cancer with interests centering around developmental therapeutics, tumor biology, mechanisms of therapeutics, predictors of response to therapy

Selected Publications

Keefe SM, Rosen MA, Robinson J, McGibney K, Marshall A, Mamtani R, Vaughn DJ, O'Dwyer PJ, Haas NB, Pryma DA: Results of a feasibility study of I-124 girentuximab (Wilex AB) in metastatic clear cell renal cell carcinoma (m ccRCC). 2014 GU Cancers Symposium ASCO Supplement, February 2014.

Keefe SM, Heitjan D, Hennessey M, Robinson J, Mykulowicz K, Marshall A, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman-Censits JH, Nathanson KL, Lal P, Pryma DA, Eliasof S, Garmey EG, Cohen RB, Haas NB: Interim Results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 (Cerulean Pharma, Inc., Cambridge, MA, USA) with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). 2014 GU Cancers Symposium ASCO Supplement, February 2014.

Keefe SM, Nathanson KL, Rathmell WK: Molecular biology of renal cell carcinoma. Seminars in Oncology 40(4): 421-8, August 2013.

Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ: Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 112(1): 13-25, July 2013.

Keefe SM, Cohen R, Eliasof S, Garmey EG, Mykulowicz KM, Pryma D, Haas NB: A Phase Ib-IIa Study Evaluating the Nanopharmaceutical CRLX101 in Combination with Bevacizumab in the Treatment of Patients with Advanced Renal Cell Carcinoma (NCT01625936). 2013 Assocation of American Cancer Research April 2013.

Shah A, Motiwala S, O'Dwyer PJ, Flaherty KT, Keefe SM: Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. 2013 Genitourinary Cancers Symposium February 2013.

Keefe SM, Lee WMF, Rosen MA: Perfusion and DCE Imaging of Renal Cancer (chapter). MR & CT Perfusion Imaging: Clinical Applications and Theoretical Principles. Lippincott Williams & Wilkins, In Press 2013.

Keefe SM, Rathmell WK, Nathanson KL: Genomic assessment of renal cell carcinoma - IN PRESS. Renal Cell Carcinoma: Molecular Targets & Clinical Applications, Third Edition. Ronald M. Bukowski, Robert Figlin, Robert Motzer (eds.). Springer Science + Business Media, 2013.

Keefe, S.M., Nathanson, K.L., Rathmell, W.K.: Molecular Biology of Kidney Cancer. Seminars in Oncology. Rini, B.I. (eds.). In Press 2013.

Kang, H. C. Tan, K. S. Keefe, S. M. Heitjan, D. F. Siegelman, E. S. Flaherty, K. T. O'Dwyer, P. J. Rosen, M. A.: MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 200(1): 120-126, December 2012.

back to top
Last updated: 01/16/2014
The Trustees of the University of Pennsylvania